How large can a drug class get once it proves it can treat obesity, diabetes and heart risk at the same time? The peptide therapeutics market offers an early answer. Valued at USD 140.9 billion in 2025, it is projected to reach USD 294.6 billion by 2033, growing at 8.7% annually from 2026. North America accounts for 61.9% of today’s revenue, but the factors that decide the next USD 130 billion, such as manufacturing capacity, oral delivery and generic competition, are only now taking shape.

Market Size and Forecast: What the Numbers Say

The peptide therapeutics market adds roughly USD 130.6 billion in revenue between 2026 and 2033 (USD 294.6 billion minus USD 164.0 billion), an increase of about 80% in seven years. One detail is easy to miss. The move from USD 140.9 billion in 2025 to USD 164.0 billion in 2026 is about 16.4%, nearly double the forecast CAGR. This is our own calculation from the report’s figures, and it suggests the market is entering a steadier growth phase after a GLP-1-fuelled surge.

Today’s revenue is concentrated in a few segments. In 2025, innovative peptides held 80.1% of revenue and metabolic disorders held 63.6%. Parenteral (injectable) administration held 84.0%, recombinant DNA technology held 80.2% of synthesis, and in-house manufacturing held 64.8%.

The more useful insight is that the dominant segments are not the fastest-growing ones. Only two sub-segments with disclosed growth rates outpace the overall 8.7% market rate: outsourced manufacturing at 8.90% and non-injectable “other” delivery routes, such as transdermal patches and implantable depots, at 9.47%. Generic peptides (6.95%), pain applications (7.47%), liquid-phase synthesis (7.62%) and Asia Pacific (7.98%) all grow below the market rate. The next wave of growth appears to depend on how peptides are made and delivered, not just which diseases they treat. Because injectables start from such a large base, the shift away from them is gradual.

Download a free sample report or claim your copy of this full market intelligence report

Key Drivers and Trends: Why Demand Keeps Rising

Metabolic disease is the engine. Rising diabetes and obesity rates feed demand, and GLP-1 receptor agonists have given the industry commercial proof. In September 2025, once-weekly injectable semaglutide was linked to a 23% lower risk of major adverse cardiovascular events than dulaglutide in nearly 60,000 US Medicare patients aged 66 or older. A July 2025 phase 2 trial of the monthly GLP-1 candidate MariTide enrolled 592 people with obesity. Participants without diabetes lost up to 16.2% of body weight over 52 weeks. This kind of evidence moves peptides from niche therapies toward mainstream cardiometabolic care.

Engineering has fixed peptides’ old weaknesses. Short half-life, enzymatic degradation and poor bioavailability once limited the category. PEGylation, lipid nanoparticle delivery and depot formulations now extend stability, while peptide-drug conjugates, cell-penetrating peptides and cyclic peptides improve target specificity. Oral semaglutide showed that peptides need not be injected, and absorption enhancers, intranasal sprays and patches are following that path.

Manufacturing is scaling up. Solid-phase and hybrid synthesis have improved yield, purity and batch consistency. In 2025, Bachem raised annual peptide capacity at its Vista, California site to nearly one metric ton and began building a large new facility in Bubendorf, Switzerland.

Cost and complexity remain the brakes. Peptide production relies on multi-step purification such as HPLC and lyophilization, and stability problems add formulation cost. Regulators including the FDA, EMA and PMDA require extensive quality and safety data. Barriers to entry are moderate to high, which keeps smaller biotechs dependent on partnerships.

Generics are opening the lower-price tier. In August 2025, the FDA approved the first generic version of Saxenda (liraglutide), allowing Teva to market a lower-cost alternative. As more peptide classes lose patent protection, this tier should widen access, even though generics grow more slowly than the overall market.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs

Major Market Players: Who Controls What

Eli Lilly and Company and Novo Nordisk A/S dominate through GLP-1 leadership in diabetes and obesity. Sanofi and Pfizer hold broad endocrine and inflammatory portfolios, while Amgen and F. Hoffmann-La Roche concentrate on oncology and rare disease peptides. Takeda, AstraZeneca and Novartis expand targeted biologic strategies. Teva, GSK, Ironwood Pharmaceuticals, Radius Health and Ipsen add competitive pressure through specialty and gastrointestinal offerings.

Recent deals show that competition is shifting from molecules to supply chains and partnerships. In December 2025, Lilly announced more than USD 6 billion for a new active ingredient facility in Huntsville, Alabama. It will make small-molecule and peptide medicines, including oral GLP-1 candidate orforglipron, with construction starting in 2026 and completion targeted for 2032. In February 2026, Lilly partnered with Zonsen PepLib Biotech to discover peptide candidates from proprietary libraries. In December 2025, Pfizer licensed YP05002 from YaoPharma for USD 150 million upfront and up to USD 1.935 billion in milestones.

Large players build in-house capacity, which explains the 64.8% share. Mid-sized biotechs buy flexibility from contract manufacturers, which explains the 8.90% outsourced growth rate. SK pharmteco’s expansion of its California peptide facility in 2024 reflects the same pressure.

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Regional Snapshot

North America’s 61.9% share reflects strong research infrastructure, high GLP-1 adoption and rapid uptake of new approvals in the U.S. Asia Pacific is projected to grow at 7.98%, supported by rising diabetes and obesity prevalence, expanding manufacturing capacity and growing access to specialty care.

Check Out Our Dedicated Business Offerings – 

• Healthcare Facility Mapping & Intelligence Platform: Map and analyze U.S. healthcare facilities. Explore now
• Prism AI: Get market intelligence backed by cited research. Try Prism AI